Robert Fekety

TL;DR: Comparison of data from this trial with data from previous studies indicates that recurrent CDD may respond to a short course of high- dose vancomycin or to longer courses of low-dose vancomYcin when either is combined with S. boulardii.

TL;DR: C difficile was isolated from hands and stools of asymptomatic hospital personnel, from sewage and soil, and from the home of a patient, and environmental isolates were toxigenic.

TL;DR: Five factors were associated with a higher risk of RCDD: the number of previous CDD episodes, onset of the initial disease in the spring, exposure to additional antibiotics for treatment of other infections, infection with immunoblot type 1 or 2 strains of C. difficile, and female gender.

TL;DR: Recurrent CDAD was found to have a lengthy course involving multiple episodes of diarrhea, abdominal cramping, nausea, and fever and may result in prolonged hospital stays, additional medical costs, and rare serious complications.

TL;DR: In patients with recurrent or relapsing colitis, treatment with either metronidazole or vancomycin is effective for that episode, but novel approaches, such as the oral or rectal introduction of competing nonpathogenic organisms, may prove to be more successful in prevention of relapses.